|
Vol 44(2010) N 5 p. 665-681; I.O. Mazunin*, N.V. Volodko, E.B. Starikovskaya, R.I. Sukernik Mitochondrial Genome and Human Mitochondrial Diseases Institute of Chemical biology and Fundamental Medicine of Siberian Branch of Russian Academy of Sciences, Novosibirsk, 630090 Russia*IMazunin@kantiana.ru Received - 2010-03-25; Accepted - 2010-04-08 Today there are described more than 400 point mutations and more than hundred of structural rearrangements of mitochondrial DNA associated with characteristic neuromuscular and other mitochondrial syndromes, from lethal in the neonatal period of life to the disease with late onset. The defects of oxidative phosphorylation are the main reasons of mitochondrial disease development. Phenotypic diversity and phenomenon of heteroplasmy are the hallmark of mitochondrial human diseases. It is necessary to assess the amount of mutant mtDNA accurately, since the level of heteroplasmy largely determines the phenotypic manifestation. In spite of tremendous progress in mitochondrial biology since the cause-and-effect relations between mtDNA mutation and the human diseases was established over 20 years ago, there is still no cure for mitochondrial diseases. mitochondrial genome, oxidative phosphorylation, mtDNA mutations, heteroplasmy, mitochondrial diseases, mitochondrial respiratory chain defect therapy |